Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abbott reports positive data from new MitraClip trial

Abbott reports positive data from new MitraClip trial

31st October 2013

Abbott has announced the publication of new clinical data that further reinforces the benefits of its first-in-class catheter-based MitraClip therapy.

The device has been shown to offer significant benefits to patients with degenerative mitral regurgitation who are at prohibitive risk for mitral valve surgery, a group who previously had no therapy options available to them.

Results published in the Journal of the American College of Cardiology showed that use of MitraClip was associated with clinically meaningful changes to quality of life, a reduction in rehospitalisation for heart failure and various functional improvements.

These results come after the device was approved by the US Food and Drug Administration last week.

Chuck Foltz, senior vice-president for vascular at Abbott, said this data, "along with clinical results from more than 2,200 patients treated with the device, confirm the benefit of the innovative MitraClip therapy for this very sick patient population".

Earlier this week, the company announced its financial results for the third quarter of 2013, during which it experienced year-on-year growth of two percent.ADNFCR-8000103-ID-801655636-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.